Cargando…
Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study
Genital warts (GWs) are common, with about 5% to 10% of people having at least one episode in their lifetime. They develop about 2–3 months after infection with human papillomavirus (HPV) genotypes 6 and 11. The prophylactic quadrivalent HPV vaccine (qHPV), protects against HPV6/11 infections and di...
Autores principales: | Dominiak-Felden, Geraldine, Gobbo, Corrado, Simondon, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492693/ https://www.ncbi.nlm.nih.gov/pubmed/26147096 http://dx.doi.org/10.1371/journal.pone.0132404 |
Ejemplares similares
-
Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study
por: Dominiak-Felden, Geraldine, et al.
Publicado: (2016) -
Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
por: Hartwig, Susanne, et al.
Publicado: (2015) -
The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis
por: Lukács, Anita, et al.
Publicado: (2020) -
Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
por: Mariani, Luciano, et al.
Publicado: (2015) -
Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
por: Hartwig, Susanne, et al.
Publicado: (2017)